DOS 2018

116 · DOS Abstracts Translation and Validation of the Southampton Dupuytren Scoring Scheme Lærke Vig Lannov, Rasmus Wejnold Jørgensen, Claus Hjorth Jensen Hand Clinic, Department of Orthopedics, Herlev-Gentofte University Hospital of Copenhagen Background: A Danish validated Patient Reported Outcome Measure (PROM) specific to Dupuytren’s Disease (DD) does currently not exist. Such a PROM would be useful in the overall assessment of DD patients. Purpose/Aimof Study: The aimof the studywas to translate the Southampton Dupuytren Scoring Scheme (SDSS) into Danish and validate the translated ver- sion of the PROM. Materials and Methods: The SDSS was translated by 5 clinicians according to guidelines by Swaine-Verdier et. al. 110 patients diagnosed with DD com- pleted the translated PROM and were asked to indicate if the PROM accurately and adequately described the inconveniences they experience due to DD. The severity of DD was assessed clinically using the Tubiana classification method. 16 patients treated with collagenase injections were re-evaluated with SDSS and Tubiana min. 4 weeks post-operatively. Reliability of the SDSS was tested in terms of internal consistency expressed as Cronbach’s alpha and test-retest ex- pressed as an intraclass correlation coefficient. Spearman’s rank correlation co- efficient was calculated for SDSS and Tubiana in order to validate the construct of SDSS against clinical evaluation of severity of the disease, and responsive- ness of the PROM was tested using point-biserial correlation and standardized response mean. Findings / Results: The overall Cronbach’s alpha was 0.758 and the intra- class correlation coefficient was 0.816 (CI 95%: 0.533-0.927, P<0.0001). Spearman’s rank correlation coefficient was 0.55 (P= 0.007) preoperatively and 0.387 (P=0.139) postoperatively. The standardized response mean was 1.96 (95% CI: 1.42- 2.48), point-biserial correlation coefficient was 0.520 (P=0.039). Conclusions: The SDSS shows great reliability, substantial responsiveness to change, and a high level of patient-approval and is therefore recommended to be used for patients with DD. 57.

RkJQdWJsaXNoZXIy NjEzNTY=